Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
公司代碼MGX
公司名稱Metagenomi Inc
上市日期Feb 09, 2024
CEOIrish (Jian)
員工數量202
證券類型Ordinary Share
年結日Feb 09
公司地址5959 Horton St
城市EMERYVILLE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94608
電話15108714880
網址https://metagenomi.co/
公司代碼MGX
上市日期Feb 09, 2024
CEOIrish (Jian)